部落运输

2021年4月13日

医学必要的:增长的生物和基因疗法意味着更多的冷链0 15 4分钟读格鲁吉亚-基于部落运输最近扩大了舰队的冷藏拖车来满足日益增长的需求来自生命科学行业。(来源:吉姆·艾伦/ FreightWaves)这是一个摘录从4月13日,2021年版的医学上必要的,医疗供应链通讯。订阅。趋势:生物药物和基因疗法的数量正在增长,和物流公司提高温控运输能力支持他们。——生物制剂药物创造了生物来源,如血液或其他细胞。他们通常比药物产生化学复杂得多。——基因疗法,生物制剂,药物替换或修改病人的基因来治疗疾病。药物在两个类别在运输过程中,需要仔细控制温度。未来:大约四分之一的药物目前需要某种形式的温度控制在运输期间,根据Rnajeet那尔吉这样,医药物流公司冷链技术的首席执行官。,他预计这一数字将跳大约三分之一的药物在未来两年。 — “With the launch of biologics, with the launch of personalized medicine and … certain gene therapy formulations, that are happening now, the need for temperature and other condition monitoring is becoming even more acute,” he said. Biologics: The market for temperature-sensitive biologics is growing faster than that of other types of drugs. Spending on biologics through Medicare Part B, which covers drugs that patients recieve at a doctor’s office or hospital, jumped from about 56% of total drug spending in 2006 to 77% in 2017, according to a Health and Human Services Department report . — In large part, that growth is because biologic drugs tend to be very expensive. The report found that biologics accounted for almost all of the program’s drug spending growth during those years. Spending on biologics through Medicare Part D has increased rapidly over the last decade. (Credit: Health and Human Services Department ) The number of patients receiving biologics also appears to be increasing. — Data from Medicare Part D , which covers prescription drugs, shows that the number of beneficiaries receiving a group of seven common biologics increased by more than 75% from 2011 to 2018. — “This trend has a couple of logistics implications,” Cedric Picaud, CEO of the Cryoport company CRYOPDP told FreightWaves. “The value of each shipment is very high. The cost of managing such medication is high. In terms of logistics, the lead time requirement is very challenging.” The response: As the number of biologic drugs and gene therapies continues to grow, logistics companies are increasing their capacity for temperature-controlled transportation. In March, Cold Chain Technologies, which previously focused on packaging, expanded the scope of its business. — The company will now offer last-mile delivery services, warehousing and point-of-care storage for temperature-controlled drugs. The goal is to provide logistics from the manufacturer to the patient, Banjeree said. Over the past two years, Cryoport has acquired several cold chain logistics companies to expand its reach. — The company grew from 57 employees at the end of 2018 to more than 625 by the end of 2020 . Tribe Transportation, a temperature-controlled trucking company based in Georgia, recently added more than 100 trailers to its fleet to meet demand from the life sciences industry. — “There are still life sciences customers out there looking for capacity to move shipments,” Executive Vice President Matt Handte told FreightWaves. “Post-vaccine, we’ve seen that continue to rise.” — The past three years have been the company’s best years for growth of both revenue and fleet size, Handte said. The virus: The coronavirus vaccine rollout has put the cold chain in the spotlight, but companies don’t expect this to be a flash in the pan. Cold Chain Technologies provides packaging for COVID-19 vaccines made by Moderna and Johnson & Johnson. The company opened a new manufacturing plant in Tennessee last year to meet the needs of the vaccine rollout, but Banjeree doesn’t expect that capacity to go to waste. — “If we plan this carefully, we could use this capacity to support COVID vaccinations outside the U.S., which will have a longer ramp down … as well as taking care of the new drugs and biologics,” he said. What’s next? Banjeree said he hopes the vaccine rollout will help logistics companies do a better job of transporting temperature-controlled drugs after the pandemic. — “How do we make sure we transform … the cold chain so that the next time this happens we are way ahead?” he said. “And use all that learning for the day-to-day shipments of drugs and pharmaceuticals.” Tags